• Explore /
  • Poster
  • / PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study.  .

PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study.  .

Abstract Poster

Authors

null

J. Maurel

Hospital Clinic i Provincial, Barcelona, Spain

J. Maurel , X. Garcia-Albeniz , C. Méndez Méndez , M. Martin-Richard , C. Pericay , R. Vera , J. Aparicio , M. Rubini , M. Cuatrecasas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session

Track

Special Sessions,Clinical Trials

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

2009-017331-18

Citation

J Clin Oncol 29: 2011 (suppl; abstr TPS164)

Abstract #

TPS164

Poster Bd #

44B

Abstract Disclosures

Similar Posters

First Author: John H. Strickler

First Author: K. Oliner

First Author: A. R. Townsend

First Author: Gargi Dan Basu